Urodynamix Technologies Ltd. Reports Fiscal 2009 First Quarter Results

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today reported its financial
results for its fiscal first quarter ended March 31, 2009, reporting a strong
increases in revenues over the prior year's first quarter. For Urodynamix's
quarter ended March 31, 2009, the Company reported revenues of $271,281, a
1,269% increase from revenues of $22,382 for the first quarter ended March 31,
2008, and a 44% increase over full year fiscal 2008. In addition the Company
increased its order backlog at March 31, 2009 to $92,576 compared to nil at the
end of the comparative quarter March 31, 2008.


The increase in revenue resulted from the first commercial sales of the URO NIRS
2000 in the quarter. "We acknowledge the exemplary performance of the management
team and the entire staff in helping to deliver a quarter of record breaking
revenue; selling, building and shipping our first significant quarter of
revenue," stated Barry Allen, President and CEO of Urodynamix Technologies Ltd.
"We are focused on developing our existing sales channels and building new
channels with new partners in new territories. We expect that these activities
will result in growing quarter over quarter sales. As our installed base grows
and we ship increased amounts of sensors we should see steady significant
improvement in gross margin."


Gross margin at 37.1% of revenue decreased from 63.9% of revenue in the quarter
to March 31, 2008. The decrease in gross margin was due to first run production
costs, low volume production runs and introductory pricing for the URO NIRS
2000. The Company expects to be able to improve gross margins through pricing
initiatives and programs to improve productivity and lower component costs.


Expenses for the three months ended March 31, 2009 were $758,853 compared to
758,909 for the comparative period of the prior year. An increase in marketing
and selling expenses, the result of business development activities to support
the URO NIRS 2000 introduction, was offset by a decrease in research and
development expenses due to the timing of development activities and the
completion of the URO NIRS 2000 commercialization program.


The net loss for the quarter ended March 31, 2009 was $655,238 or $0.01 per
share basic and diluted, as compared to a net loss of $722,081 or $0.01 per
share basic and diluted for the quarter ended March 31, 2008. The decrease in
the loss was due primarily to the gross margin generated on sales in the
quarter.


As of March 31, 2009, cash and cash equivalents decreased from $2,262,794 to
$1,505,641 at December 31, 2008. Working capital at March 31, 2009 was
$1,303,972 and the Company remains debt free.


About Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd. is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic
hyperplasia, and traumatic increases in intra-abdominal pressure that cause
abdominal compartment syndrome. Urodynamix's breakthrough medical technology has
the potential to beneficially affect more than 200 million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.

Urodynamix Technologies Ltd. (TSXV:URO)
Graphique Historique de l'Action
De Juil 2024 à Août 2024